Sinocelltech Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS25
PHASE 3 / 2-39
RECRUITING13
READOUTS ≤12 MONTHS9
READOUT SLIPPED >6 MO0%
Delay Index: of 8 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Sinocelltech Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MAOP3 NCT04709328 |
P2/3 | Not yet recruiting | COVID-19; SARS-CoV-2 | 690 | 2022-01-01 |
| Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell) NCT06041061 |
P3 | Active, not recruiting | HPV InfectioN; HPV-Related Carcinoma | 18000 | 2024-03 |
| Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose NCT06801509 |
P1/2 | Not yet recruiting | Herpes Zoster | 540 | 2025-11-10 |
| SCTT11 NCT06769984 |
P1/2 | Not yet recruiting | TED | 100 | 2026-06-24 |
| SCT520FF NCT06672536 |
P1/2 | Recruiting | nAMD | 82 | 2026-09-23 |
| SCT650C NCT07244510 |
P2 | Recruiting | Hidradenitis Suppurativa (HS) | 60 | 2027-03-12 |
| SCTC21C NCT07538154 |
P1/2 | Not yet recruiting | Systemic Lupus Erythematosus (SLE) | 159 | 2027-04 |
| SCTB41 NCT06600022 |
P1/2 | Recruiting | Advanced Malignant Solid Tumours | 441 | 2027-04-30 |
| SCTB35 injection NCT06841042 |
P1/2 | Recruiting | System Lupus Erythematosus | 168 | 2027-05 |
| SCTB14 NCT07362459 |
P3 | Recruiting | Non-Small Cell Lung Carcinoma (NSCLC) | 246 | 2027-07 |
| SCTV02 NCT06754605 |
P1/2 | Recruiting | Respiratory Syncytial Virus | 480 | 2027-07-30 |
| SCTC21C NCT06774664 |
P1/2 | Not yet recruiting | IgA Nephropathy | 99 | 2027-09 |
| SCTB39G NCT07077252 |
P1/2 | Not yet recruiting | Advanced Malignant Solid Tumor | 30 | 2027-09-26 |
| SCTB35 injection NCT07570823 |
P3 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma | 101 | 2027-11 |
| SCTC21C NCT07388602 |
P3 | Recruiting | Amyloidosis | 90 | 2027-12 |
| SCTC21C NCT07297329 |
P3 | Recruiting | Multiple Myeloma (MM) | 292 | 2027-12 |
| SCTB14 NCT06304818 |
P1/2 | Not yet recruiting | Advanced Malignant Solid Tumours | 515 | 2027-12-30 |
| SCTB35 injection NCT07562022 |
P3 | Recruiting | Follicular Lymphoma (FL) | 93 | 2028-05 |
| SCTB39-1 NCT07050641 |
P1/2 | Recruiting | Advanced Malignant Solid Tumor | 110 | 2028-06-30 |
| SCTB35 injection NCT07819188 |
P1/2 | Not yet recruiting | NHL - Non-Hodgkin's Lymphoma | 90 | 2028-09-30 |
| SCTB41 NCT07609251 |
P2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 90 | 2028-10 |
| SCT800 prophylaxis and treatment for bleeding events NCT07437404 |
P3 | Recruiting | Haemophilia A | 36 | 2028-12-26 |
| SCTB41+SCTB39-1 NCT07594028 |
P1/2 | Not yet recruiting | Advanced Malignant Solid Tumor | 126 | 2029-05-30 |
| SCTB41+SCTB39G NCT07665970 |
P1/2 | Not yet recruiting | Advanced Malignant Solid Tumors | 112 | 2029-06-30 |
| SCTB41 NCT07662395 |
P2/3 | Recruiting | Double Blind | 410 | 2030-01-24 |